RCPT Profile
Receptos, Inc. (RCPT) was a biopharmaceutical company focused on the development of therapeutics for immune and metabolic diseases. The company was acquired by Celgene Corporation in 2015.
Receptos had a particular focus on developing therapies for autoimmune diseases and inflammatory disorders, including multiple sclerosis, inflammatory bowel disease, and psoriasis. The company's lead drug candidate was ozanimod, an oral therapy that targeted the S1P1 receptor. Ozanimod was being developed for the treatment of relapsing multiple sclerosis and ulcerative colitis.
In July 2015, Celgene announced that it had agreed to acquire Receptos for $7.2 billion. The acquisition was completed in August 2015. Celgene continued to develop ozanimod, which was approved by the U.S. Food and Drug Administration (FDA) in March 2019 for the treatment of relapsing forms of multiple sclerosis.
|
